Prosecution Insights
Prosecution Insights
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBOTT, KODYE LEE | 1 | 57.7% | +64.7% |
| HASTINGS, ALISON AZAR | 1 | 63.3% | +40.3% |
| COLEMAN, BRENDA LIBBY | 1 | 74.7% | +15.5% |
| MOORE, SUSANNA | 1 | 67.9% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | — |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | — |
| 18719745 | SMALL MOLECULE DRUGS THAT REDUCE PROTEIN AGGREGATION | HASTINGS, ALISON AZAR | — |
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | — |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | 1634 | §112 | Final Rejection | — | Pending | Nov 20, 2024 |
| 18719745 | SMALL MOLECULE DRUGS THAT REDUCE PROTEIN AGGREGATION | HASTINGS, ALISON AZAR | — | §102DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | 1624 | §102§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | 1624 | §102§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial